These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4335 related articles for article (PubMed ID: 25838375)

  • 1. Neoantigens in cancer immunotherapy.
    Schumacher TN; Schreiber RD
    Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
    Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB
    Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Links between genetics and immunology: mutations and antigens.
    Ayyoub M
    Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing neoantigen-targeted T cell-based treatments for solid tumors.
    Yamamoto TN; Kishton RJ; Restifo NP
    Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
    Bethune MT; Joglekar AV
    Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Neoantigens for Personalised Immunotherapy.
    Pritchard AL
    BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of neoantigens and development of antigen-specific immunotherapy].
    Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
    Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of neoantigens in response to immune checkpoint blockade.
    Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
    Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting neoantigens for cancer immunotherapy.
    Lu YC; Robbins PF
    Int Immunol; 2016 Jul; 28(7):365-70. PubMed ID: 27208041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
    Jardim DL; Goodman A; de Melo Gagliato D; Kurzrock R
    Cancer Cell; 2021 Feb; 39(2):154-173. PubMed ID: 33125859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study May Change Approach to Immunotherapy.
    Cancer Discov; 2016 May; 6(5):OF1. PubMed ID: 27012834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
    Wang Y; Shi T; Song X; Liu B; Wei J
    Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation-Derived Neoantigens for Cancer Immunotherapy.
    Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
    Front Immunol; 2019; 10():1856. PubMed ID: 31440245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 217.